Compounders Research Compare

Actuate Therapeutics Inc(ACTU)

Biotechnology · Fort Worth, TX

$0.87+0.06 (+6.83%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Actuate Therapeutics Inc

Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.

Fort Worth, TX

12 employees

actuatetherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Daniel Schmitt

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T12:45:14.918Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:45:14.918Z.

Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 20,932,728
Total debt · period ending 2026-06-30: 404,991
Cash · period ending 2026-06-30: 4,425,841
TTM operating EBITDA · period ending 2026-06-30: -20,772,595

FMP input reference: a29a88061d86e64317c53e71c63756e58f7ffa0b55551e6148327154cc786467

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ACTU EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

ACTU Competitors' EV/EBITDA Ratio

Actuate Therapeutics Inc

Current

Market Cap

$20.93M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aytu BioPharma, Inc.

Market Cap

$21.90M

EV/EBITDA Ratio

N/A

TTM Avg

6.88x

3Y Avg

5.95x

5Y Avg

5.95x

Cosmos Health Inc.

Market Cap

$18.82M

EV/EBITDA Ratio

N/A

TTM Avg

47.55x

3Y Avg

64.91x

5Y Avg

64.91x

Estrella Immunopharma, Inc.

Market Cap

$18.77M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Atossa Therapeutics, Inc.

Market Cap

$24.44M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Bionano Genomics, Inc.

Market Cap

$16.58M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Dyadic International, Inc.

Market Cap

$16.54M

EV/EBITDA Ratio

N/A

TTM Avg

95.14x

3Y Avg

74.72x

5Y Avg

74.72x

ABVC BioPharma, Inc.

Market Cap

$25.48M

EV/EBITDA Ratio

N/A

TTM Avg

11456.84x

3Y Avg

11456.84x

5Y Avg

11456.84x

BioCardia, Inc.

Market Cap

$16.22M

EV/EBITDA Ratio

N/A

TTM Avg

30.33x

3Y Avg

30.26x

5Y Avg

30.26x

Allarity Therapeutics, Inc.

Market Cap

$15.91M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Actuate Therapeutics Inc (ACTU)	$20.93M	N/A	N/A	N/A	N/A
Aytu BioPharma, Inc. (AYTU)vs ›	$21.90M	N/A	6.88x	5.95x	5.95x
Cosmos Health Inc. (COSM)vs ›	$18.82M	N/A	47.55x	64.91x	64.91x
Estrella Immunopharma, Inc. (ESLA)vs ›	$18.77M	N/A	N/A	N/A	N/A
Atossa Therapeutics, Inc. (ATOS)vs ›	$24.44M	N/A	N/A	N/A	N/A
Bionano Genomics, Inc. (BNGO)vs ›	$16.58M	N/A	N/A	N/A	N/A
Dyadic International, Inc. (DYAI)vs ›	$16.54M	N/A	95.14x	74.72x	74.72x
ABVC BioPharma, Inc. (ABVC)vs ›	$25.48M	N/A	11456.84x	11456.84x	11456.84x
BioCardia, Inc. (BCDA)vs ›	$16.22M	N/A	30.33x	30.26x	30.26x
Allarity Therapeutics, Inc. (ALLR)vs ›	$15.91M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics